These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1967740)

  • 1. GISSI-2: mortality plus extensive left-ventricular damage as "end-point".
    De Vita C; Franzosi MG; Geraci E; Maggioni AP; Mauri F; Mezzanotte G; Tavazzi L; Tognoni G; Volpi A
    Lancet; 1990 Feb; 335(8684):289. PubMed ID: 1967740
    [No Abstract]   [Full Text] [Related]  

  • 2. [GISSI-2; the beginning of the end or the end of the beginning for tissue plasminogen activator in acute myocardial infarct?].
    Lubsen J
    Ned Tijdschr Geneeskd; 1990 May; 134(19):940-4. PubMed ID: 2112233
    [No Abstract]   [Full Text] [Related]  

  • 3. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.
    Collins R; Peto R; Parish S; Sleight P
    Am J Cardiol; 1993 May; 71(12):1127-30. PubMed ID: 8475887
    [No Abstract]   [Full Text] [Related]  

  • 4. [The predictive value for major arrhythmic events of ventricular arrhythmias, particularly nonsustained ventricular tachycardias, in the subacute phase of a fibrinolyzed infarct. An analysis of GISSI-2 data. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].
    Giani P; Avanzini F; Bagliani G; Galati A; Pucci P; Santoro E
    G Ital Cardiol; 1995 Jan; 25(1):77-87. PubMed ID: 7642014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
    Negrini M
    G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of streptokinase and tissue plasminogen activator on left ventricular function.
    White HD
    Adv Exp Med Biol; 1990; 281():383-7. PubMed ID: 2129375
    [No Abstract]   [Full Text] [Related]  

  • 7. [GISSI 2; the beginning of the end or the end of the beginning for tissue plasminogen activator in acute myocardial infarct?].
    Verheugt FW
    Ned Tijdschr Geneeskd; 1990 Sep; 134(35):1711-2. PubMed ID: 2120596
    [No Abstract]   [Full Text] [Related]  

  • 8. Trials of the European Working Party on streptokinase and of the European Cooperative Study Group on alteplase in patients with acute myocardial infarction. European Investigators.
    Verstraete M
    J Interv Cardiol; 1995 Dec; 8(6):611-21. PubMed ID: 10172727
    [No Abstract]   [Full Text] [Related]  

  • 9. Streptokinase and tissue plasminogen activator in acute myocardial infarction.
    Brewer CC; Markis JE
    Heart Lung; 1986 Nov; 15(6):552-8. PubMed ID: 3095269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atenolol i.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. The GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].
    Mafrici A; Mauri F; Maggioni AP; Franzosi MG; Santoro L; De Vita C
    G Ital Cardiol; 1995 Mar; 25(3):353-64. PubMed ID: 7642042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last.
    Bassand JP
    Eur Heart J; 1994 Jan; 15(1):2-4. PubMed ID: 8174579
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
    Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative evaluation between streptokinase and r-TPA in limiting the myocardial damage during an acute myocardial infarct. An echocardiographic study].
    Morelloni S; Fasciolo L; Freggiaro V; Corazza M; Pareti G; Davi R; Allegri M
    Clin Ter; 1990 Dec; 135(5):359-65. PubMed ID: 2150366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Streptokinase or tissue plasminogen activator and left ventricular function after myocardial infarction.
    N Engl J Med; 1989 Sep; 321(10):687-9. PubMed ID: 2505074
    [No Abstract]   [Full Text] [Related]  

  • 15. The rt-PA versus streptokinase. Controversy--II.
    Braunwald E; Knatterud G; Passamani E
    J Am Coll Cardiol; 1992 Apr; 19(5):1116-9. PubMed ID: 1552103
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction].
    López-Sendón JL
    Rev Esp Cardiol; 1992; 45 Suppl 2():9-20. PubMed ID: 1475514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tissue-type plasminogen activator (t-PA): comments on results of the GISSI-2 study].
    Turazza FM
    Medicina (Firenze); 1990; 10(2):193-4. PubMed ID: 2125681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The place of thrombolysis in the management of cerebral embolism after heart valve replacement.
    Wardlaw JM
    J Heart Valve Dis; 1994 Nov; 3(6):611-2. PubMed ID: 8000603
    [No Abstract]   [Full Text] [Related]  

  • 19. The rt-PA versus streptokinase. Controversy--I.
    Lenfant C
    J Am Coll Cardiol; 1992 Apr; 19(5):1116. PubMed ID: 1348064
    [No Abstract]   [Full Text] [Related]  

  • 20. Perspectives on therapeutic interventions in patients with acute myocardial infarction: viewpoints after the GISSI-2 results.
    Maggioni AP; Franzosi MG; Malacrida R; Tognoni G
    Clin Cardiol; 1991 Jul; 14(7):549-56. PubMed ID: 1747963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.